Compact 256-channel multi-well microelectrode array system for in vitro neuropharmacology test
Daejeong Kim1, Hongki Kang, Yoonkey Nam
1Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. ynam@kaist.ac.kr.
Lab on a Chip
|August 14, 2020
Summary
This study presents a compact, custom microelectrode array (MEA) platform for high-throughput neuronal drug testing. The developed system offers a cost-effective and customizable solution for analyzing neurophysiological effects of compounds.
Area of Science:
- Neuroscience
- Electrophysiology
- Pharmacology
Background:
- Microelectrode arrays (MEAs) are crucial for measuring neuronal activity.
- Existing multi-well MEA systems are costly, bulky, and lack customizability for drug testing.
- There is a need for accessible, high-throughput electrophysiological drug screening platforms.
Purpose of the Study:
- To develop a compact, cost-effective, and customizable microelectrode array (MEA) based drug testing platform.
- To enable high-throughput analysis of neurophysiological effects of pharmacological compounds on cultured neurons.
- To overcome limitations of commercial MEA systems in drug discovery research.
Main Methods:
- Developed a custom-designed, compact 256-channel multi-well MEA integrated into a microscope slide.
- Utilized a commercial application-specific integrated circuit (ASIC) chip for neural recording.
- Applied four synaptic modulators (NMDA, AMPA, bicuculline, ATP) to cultured neurons on the MEA.
- Analyzed neural spike activity to assess neurophysiological responses to drug perturbations.
Main Results:
- Successfully implemented a compact multi-well MEA platform with 256 electrodes across 16 wells.
- Demonstrated the platform's capability to detect and analyze neurophysiological effects of synaptic modulators.
- Achieved reduced platform size and cost compared to conventional multi-well MEA systems.
- Facilitated accessible analysis of neuropharmacological compounds through commercial amplifier chips and custom interface design.
Conclusions:
- The developed MEA drug testing platform offers a more accessible, cost-effective, and customizable alternative for neuropharmacological studies.
- This platform enhances the feasibility of high-throughput electrophysiological drug screening.
- The custom design and use of commercial components streamline the analysis of drug effects on neuronal network activity.
